The Food and Drug Administration yesterday posted updated comparative performance data for molecular tests to diagnose the COVID-19 virus.

Test developers, in order to receive emergency use authorization, are required to assess their test’s performance against a reference panel of viral samples.

In FDA’s data, a lower product LoD (limit of detection) indicates a test’s ability to detect a smaller amount of viral material in a given sample, signaling a more sensitive test. FDA updates the data as it receives additional results to help inform laboratories, health care providers and patients about the relative performance of available tests.

Related News Articles

Headline
More hospitals are implementing policies and programs to address the mental and emotional wellbeing of staff members, writes American Organization for Nursing…
Headline
A study released today by the Centers for Disease Control and Prevention estimates 299,028 more deaths than expected occurred in the United States between Jan…
Headline
The Department of Health and Human Services’ Office of Intergovernmental Affairs will host an Oct. 22 webinar at 1 p.m. ET on the Centers for Medicare &…
Blog
In 2019, the term “burnout” was added to the World Health Organization’s International Classification of Diseases (ICD). According to the ICD, burnout is a “…
Headline
The AABB, America’s Blood Centers and the American Red Cross Friday urged eligible individuals to donate blood, calling the nation’s blood supply “critically…
Headline
A new analysis by Global Health 50/50, an initiative to advance gender equality in global health, sheds light on sex disparities in COVID-19 deaths.…